Navigation Links
Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
Date:3/3/2008

lion cash upfront (expensed as R&D for US GAAP purposes) and made an equity investment in Renovo Group plc of US$50 million (at a subscription price of GBP2 per share, which at the date of the original announcement represented approximately 7% of Renovo's share capital).

On the FDA's acceptance of the filing of the biologics license application for JUVISTA, Shire will pay US$25 million and on FDA approval, between US$50 and US$150 million depending on the characteristics of the approved product labelling. In addition, Shire will pay to Renovo royalties on sales of JUVISTA and milestone payments of up to US$525 million on the achievement of significant sales targets.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results coul
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
2. DW Healthcare Partners Announces the Sale of Tandem Labs
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
5. MarketResearch.com Announces Distribution of Spectra Intelligence Research
6. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
7. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
8. Wyeth Announces Executive Change in Finance Organization
9. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
10. Pharmacopeia Announces Management Team Changes
11. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... ActiGraph, a leading provider of objective physical ... community, announced today that Dr. Victor KR Matsudo has ... Scientific Director of the Physical Fitness Research Center of ... at Gama Filho University and the Chairman of the ... of Health of São Paulo State, Brazil. , ...
(Date:6/18/2013)... June 18, 2013 Kitware , ... announces a new Fast-Track award from the U.S. Department ... environment (IDAE) for the nuclear power industry. , Construction ... more than 30 years, but the United States’ nuclear ... gains in power plant utilization through improved refueling, maintenance, ...
(Date:6/17/2013)... As a leader in the skincare industry, the team ... for acne, rosacea, and eczema. As part of Acne and ... Rosacea Society) has dedicated a month to creating awareness about ... on treatment options. Probiotic Action follows in the footsteps of ... via social networks and online resources for the acne and ...
(Date:6/17/2013)... LONDON and BOSTON , June ... market is set to reach $127 billion by 2018, accounting ... to the recently released Orphan Drug Report 2013 ... its clients, needs in regard to this growing segment of ... core product database to include in-depth, fact-based orphan drug analysis ...
Breaking Biology Technology:Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board 2Kitware to Develop an Open-Source HPC Design-Analysis Environment for Nuclear Energy Research 2Acne and Rosacea Awareness Month: Probiotic Action Announces their Daily News Updates with Insight on the Most Common Skin Conditions 2Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3
... increase 4.2% vs. prior year -DENVER, May 14 Corgenix ... marketer of diagnostic test kits, today filed its third quarter ... the company,s sales have increased during the quarter ended March ... Some of the results highlighted by the report are as ...
... Program Combines Histology, Biomarkers and Non-Invasive Imaging to Demonstrate ... FRANCISCO, May 14 VIA Pharmaceuticals, Inc. ... on the development of compounds for the treatment of ... completed enrollment in a Phase 2 clinical trial of ...
... Dollar Collaboration" -Toronto Stock Exchange Symbol: MSEDMONTON, May ... a leading developer in the treatment of multiple ... Vice President, Commercial Development, BioMS Medical and Mr. ... Lilly and Company, will take part in a ...
Cached Biology Technology:Corgenix Reports Third Quarter Fiscal 2009 Financial Results 2Corgenix Reports Third Quarter Fiscal 2009 Financial Results 3Corgenix Reports Third Quarter Fiscal 2009 Financial Results 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5BioMS Medical to participate in panel session at Bio International Convention 2009 2
(Date:6/18/2013)... DNA and this modification can occur in millions ... scientists believed that this epigenetic phenomenon actively reduced ... of researchers from the University of Geneva (UNIGE), ... the Faculty of Medicine, reveals that this is ... may play both a passive and active role ...
(Date:6/17/2013)... Women in the U.S. exposed to high levels of ... to have a child with autism as women who lived ... from Harvard School of Public Health (HSPH). It is the ... air pollution across the U.S. , "Our findings raise concerns ... women in our study lived in areas where risk of ...
(Date:6/17/2013)... 2013 An international team led by scientists at ... Institute and Albert Einstein College of Medicine of Yeshiva ... that attacks the tuberculosis (TB) bacterium in two different ... solve one of the major global health crises of ... strains," said Peter G. Schultz, the Scripps Family Chair ...
Breaking Biology News(10 mins):The secret of DNA methylation 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4
... Ill Lincoln Park Zoo has been awarded a ... research division, the Urban Wildlife Institute, which will focus ... and utilize sound science to create best practice conflict ... ecology with epidemiology research to create a holistic approach ...
... who has ever battled a stuck zipper knows it,s a ... -- and then to pull hard. , A Cornell research ... mapping the hiccups, stoppages and forces along the way, they ... expressed within cells. , The research, "High-resolution dynamic mapping of ...
... available in German . , The ... is able to rapidly ,and efficiently detoxify chemical warfare ... Tokyo subway attacks in 1995. A detailed understanding ,of ... ,necessary for efforts aiming to improve their properties. A ...
Cached Biology News:Lincoln Park Zoo awarded $1.5 million grant for new research institute 2Researchers 'unzip' molecules to measure interactions keeping DNA packed in cells 2Structure of enzyme against chemical warfare agents determined 2
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... FROM LIGHT. Useful in cell activation experiments when calcium ... TLC. Soluble in DMSO or EtOH. For ... stock in DMSO is recommended. Microliter amounts of this ... rapid mixing (e.g. 10 μl into 5 ml of ...
... poorly to Protein A and, until recently, no ... step IgM purification. Standard methods for IgM purification ... not effective for removing all of the major ... Pierce has developed an easy-to-use affinity ...
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... FROM MOISTURE. Protein synthesis inhibitor. Inhibits ... nascent polypeptide chains. Induces DNA fragmentation ... leukemia cells. Purity: ≥98% by ...
Biology Products: